Adaptive Biotechnologies Corp (ADPT) concluded trading on Thursday at a closing price of $8.22, with 3.12 million shares of worth about $25.67 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 97.12% during that period and on March 27, 2025 the price saw a loss of about -0.24%. Currently the company’s common shares owned by public are about 147.77M shares, out of which, 141.74M shares are available for trading.
Stock saw a price change of 6.06% in past 5 days and over the past one month there was a price change of -1.67%. Year-to-date (YTD), ADPT shares are showing a performance of 37.11% which increased to 163.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.28 but also hit the highest price of $9.01 during that period. The average intraday trading volume for Adaptive Biotechnologies Corp shares is 1.72 million. The stock is currently trading 5.38% above its 20-day simple moving average (SMA20), while that difference is up 4.64% for SMA50 and it goes to 46.21% higher than SMA200.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) currently have 147.77M outstanding shares and institutions hold larger chunk of about 92.59% of that.
The stock has a current market capitalization of $1.22B and its 3Y-monthly beta is at 1.71. It has posted earnings per share of -$1.08 in the same period. It has Quick Ratio of 2.81 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADPT, volatility over the week remained 6.76% while standing at 9.38% over the month.
Stock’s fiscal year EPS is expected to rise by 14.71% while it is estimated to increase by 24.31% in next year. EPS is likely to grow at an annualized rate of 28.67% for next 5-years, compared to annual growth of -1.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on March 21, 2025 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by JP Morgan stated Adaptive Biotechnologies Corp (ADPT) stock as an Overweight in their note to investors on July 05, 2023, suggesting a price target of $15 for the stock. On January 05, 2023, Scotiabank Initiated their recommendations, while on December 21, 2022, Piper Sandler Upgrade their ratings for the stock with a price target of $14. Stock get an Underperform rating from Credit Suisse on August 25, 2022.
